Search

Search Constraints

You searched for: Author/Creator Nagane, Motoo

Search Results

1. 12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. Issue 5 (26th October 2021)

2. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma. Issue 3 (30th November 2018)

4. ACT-19 A REPORT OF PHASE I PART OF PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFORMIN AND TEMOZOLOMIDE FOR GLIOBLASTOMA. (3rd December 2022)

5. ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS. (11th November 2019)

6. ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. (5th November 2018)

7. BIOM-27. PROGNOSTIC SIGNIFICANCE OF EXTENT OF RESECTION IN GLIOMA ACCORDING TO THE 2021 WHO CLASSIFICATION. (14th November 2022)

8. BOT-3 Prognostic Factors of CNS Germ Cell Tumors; Molecular and Histopathological Analyses on 154 Cases from the iGCT Consortium. (6th December 2021)

10. BT-4 PROGNOSIS OF HISTOLOGICALLY DIAGNOSED GRADE 2-3 IDH-WILD TYPE DIFFUSE GLIOMAS TREATED WITH RADIATION AND TEMOZOLOMIDE. (3rd December 2022)